JP2021536265A5 - - Google Patents
Info
- Publication number
- JP2021536265A5 JP2021536265A5 JP2021512773A JP2021512773A JP2021536265A5 JP 2021536265 A5 JP2021536265 A5 JP 2021536265A5 JP 2021512773 A JP2021512773 A JP 2021512773A JP 2021512773 A JP2021512773 A JP 2021512773A JP 2021536265 A5 JP2021536265 A5 JP 2021536265A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- modified hematopoietic
- nucleic acid
- nucleotide sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728306P | 2018-09-07 | 2018-09-07 | |
| US201862728338P | 2018-09-07 | 2018-09-07 | |
| US62/728,338 | 2018-09-07 | ||
| US62/728,306 | 2018-09-07 | ||
| PCT/US2019/050013 WO2020051493A1 (en) | 2018-09-07 | 2019-09-06 | Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021536265A JP2021536265A (ja) | 2021-12-27 |
| JP2021536265A5 true JP2021536265A5 (enExample) | 2022-09-14 |
Family
ID=69722785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512773A Pending JP2021536265A (ja) | 2018-09-07 | 2019-09-06 | 細胞内乳酸濃度を調節するトランス代謝分子と組み合わせたキメラ受容体ポリペプチド及びその治療的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210340219A1 (enExample) |
| EP (1) | EP3847260A4 (enExample) |
| JP (1) | JP2021536265A (enExample) |
| KR (1) | KR20210056377A (enExample) |
| CN (1) | CN112888786A (enExample) |
| AU (1) | AU2019336229A1 (enExample) |
| CA (1) | CA3111706A1 (enExample) |
| IL (1) | IL281294A (enExample) |
| WO (1) | WO2020051493A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019299439C1 (en) * | 2018-07-03 | 2025-06-26 | Sotio Biotech, Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4161536A4 (en) * | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| US20230265205A1 (en) * | 2020-08-10 | 2023-08-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Metabolism-based chimeric antigen receptors and methods of treatment |
| US20240197880A1 (en) * | 2021-04-30 | 2024-06-20 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| AU2022388928A1 (en) | 2021-11-16 | 2024-05-16 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| EP4469067A1 (en) * | 2022-01-25 | 2024-12-04 | Ramot at Tel-Aviv University Ltd. | Engineering b cells to express chimeric antigen receptors (cars) and uses thereof for t cell independent activation |
| CN114410588B (zh) * | 2022-01-29 | 2022-11-04 | 西安电子科技大学 | 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用 |
| CN114478806B (zh) * | 2022-04-14 | 2022-07-01 | 呈诺再生医学科技(北京)有限公司 | 一种提升免疫细胞杀伤活性的嵌合受体及其应用 |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| US20240352533A1 (en) * | 2023-04-24 | 2024-10-24 | Nantbio, Inc. | Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment |
| CN116286666B (zh) * | 2023-05-15 | 2023-08-04 | 成都云测医学生物技术有限公司 | 滋养层细胞及其制备方法、应用和扩增nk细胞的方法 |
| WO2025235862A1 (en) * | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450112B2 (en) * | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
| US20130316391A1 (en) * | 2010-12-29 | 2013-11-28 | Sigmaaldrich Co., LLC | Cells having disrupted expression of proteins involved in adme and toxicology processes |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| SI3151672T1 (sl) * | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| WO2016090365A1 (en) * | 2014-12-05 | 2016-06-09 | Dessain Scott Kendall | Pdk1 binding molecules and uses thereof |
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| JP6735224B2 (ja) * | 2016-01-28 | 2020-08-05 | 花王株式会社 | アストロサイトのグルコース代謝活性化剤 |
| EP3430036A4 (en) * | 2016-03-18 | 2019-08-14 | Unum Therapeutics | MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY |
| RU2019104074A (ru) * | 2016-07-15 | 2020-08-18 | Посейда Терапьютикс, Инк. | Химерные рецепторы антигенов и способы их применения |
| US12304935B2 (en) * | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| WO2018027042A1 (en) * | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
| EP3548049A4 (en) * | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| EP3585394A4 (en) * | 2017-02-23 | 2021-06-30 | Olema Pharmaceuticals, Inc. | COMPOSITIONS AND PROCEDURES FOR REGULATING IMMUNE SYSTEM ACTIVITY |
-
2019
- 2019-09-06 KR KR1020217009807A patent/KR20210056377A/ko not_active Ceased
- 2019-09-06 WO PCT/US2019/050013 patent/WO2020051493A1/en not_active Ceased
- 2019-09-06 EP EP19857632.4A patent/EP3847260A4/en not_active Withdrawn
- 2019-09-06 CN CN201980067513.5A patent/CN112888786A/zh active Pending
- 2019-09-06 AU AU2019336229A patent/AU2019336229A1/en not_active Abandoned
- 2019-09-06 JP JP2021512773A patent/JP2021536265A/ja active Pending
- 2019-09-06 CA CA3111706A patent/CA3111706A1/en active Pending
- 2019-09-06 US US17/274,021 patent/US20210340219A1/en not_active Abandoned
-
2021
- 2021-03-07 IL IL281294A patent/IL281294A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536265A5 (enExample) | ||
| JP2021529559A5 (enExample) | ||
| JP2021534740A5 (enExample) | ||
| US12410248B2 (en) | Chimeric antigen receptor and its use | |
| US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| CN112074279B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| Nolan et al. | Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA | |
| JP7175769B2 (ja) | 改善された養子ｔ細胞療法 | |
| US10828355B2 (en) | Use of car and bite technology coupled with an ScFv from an antibody against human thymidine kinase 1 to specifically target tumors | |
| CN107523547A (zh) | 一种高效稳定表达抑制性抗体的car‑t细胞及其用途 | |
| US11332513B2 (en) | Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain | |
| JP2024536859A5 (enExample) | ||
| CN105153315A (zh) | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 | |
| Vyas et al. | Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia | |
| US20240277845A1 (en) | Antibody-nkg2d ligand domain fusion protein | |
| CN116033919A (zh) | 用于免疫细胞中衔接子的诱导型表达的系统 | |
| CA3220875A1 (en) | Antibody-nkg2d ligand domain fusion protein | |
| Li et al. | Genetically modified T-cells affinity to tumor cells-development of adoptive T-cell immunotherapy | |
| CN119301157A (zh) | 用于癌症治疗的抗活化的Trop-2的嵌合抗原受体构建体 | |
| NZ772146B2 (en) | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof | |
| JP2024505093A5 (enExample) | ||
| NZ772146A (en) | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof | |
| WO2025191154A1 (en) | Therapeutic agents | |
| RU2024105406A (ru) | Клетки, экспрессирующие il-10, для улучшенной иммунотерапии рака |